Acutaas Chemicals: Q1 FY27 Earnings & Strategic Update

Executive Summary Acutaas Chemicals delivered a robust operational beat for the June quarter, marked by substantial year-over-year growth across all key financial parameters and sharp margin expansion. Despite the strong earnings print and reaffirmed full-year guidance, the stock experienced a near-term correction, trading approximately 5% lower to settle around ₹3,290. Financial Highlights Revenue Growth: Top-line revenue surged 59.1% YoY to ₹329.7 crore, up from ₹207.2 crore in the year-ago period. Net Profit (PAT): Profit after tax jumped 67.7% YoY to ₹74.3 crore, compared to ₹44.3 crore last year. Operating Margins: EBITDA more than doubled to ₹113.1 crore (from ₹50.9 crore). Consequently, EBITDA margins expanded dramatically to 34.3% (up from 24.6%), supported by enhanced production and operational efficiencies. Gross Margins: Improved by 466 basis points YoY, reaching 57.9%. Segment-Wise Performance Business Segment YoY Revenue Growth Key Drivers Advanced Intermediates +77.0% Sustained momentum in the core business and robust growth in the CDMO division. Specialty Chemicals -10.6% A muted performance in commodity chemicals offset strong growth within the BFC division. Management Outlook & Strategic Milestones FY27 Guidance Reaffirmed: Executive Chairman and Managing Director Naresh Patel reiterated the company's full-year outlook, maintaining a target of 25% revenue growth alongside stable operating margins. ESG Milestone: The company successfully secured the Responsible Care certification from the Indian Chemical Council, reflecting adherence to stringent safety and operational standards. Market Context: While the stock saw intraday selling pressure post-results (falling up to 6%), it remains a significant long-term wealth creator. Acutaas is currently trading up nearly 5x from its September 2021 IPO issue price of ₹610 per share.